HNRNPU Antibodies

Structure of HNRNPU

HNRNPU is a nuclear protein with a molecular weight of approximately 120 kDa, and its size is relatively conserved among different species. This protein contains multiple functional domains and mainly recognizes target transcripts through its RNA-binding region, participating in pre-RNA splicing, stability regulation, and maintenance of chromatin structure.

The structure of the HNRNPU protein consists of an N-terminal DNA-binding domain, a central RNA recognition motif, and a C-terminal glycine-rich region. These domains work together to mediate its interaction with nucleic acid molecules. Its unique SPRY domain is involved in protein-protein interactions, enabling HNRNPU to act as a molecular scaffold for recruiting various splicing factors and chromatin remodeling complexes. This protein specifically recognizes GU-rich sequences through its RGG box RNA-binding domain and plays a central hub role in the post-transcriptional regulatory network. Abnormalities in its structure are closely associated with various tumors and neurodevelopmental disorders.

Fig. 1 Schematic illustration of HnRNPU-mediated ferroptosis inhibition.¹

Key structural properties of HNRNPU:

• Contains RNA binding domain, capable of recognizing target transcripts
• Has DNA binding domain, involved in chromatin regulation
• SPRY domain mediates protein-protein interactions
• Glycine-rich region maintains protein stability
• Nuclear localization signal guides its distribution within the nucleus

Functions of HNRNPU

HNRNPU, as a multifunctional RNA-binding protein, plays a central role in gene expression regulation. Its main biological functions include:

HNRNPU, through its multi-domain characteristics, integrates RNA metabolism and chromatin dynamics, exerting dual regulatory effects in neural development and tumor formation. Abnormalities in its function can lead to splicing disorders, genomic instability, and dysregulation of signaling pathways.

Applications of HNRNPU and HNRNPU Antibody in Literature

1. Song, Huajie, et al. "RETRACTED ARTICLE: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression." Journal of hematology & oncology 13.1 (2020): 24. https://doi.org/10.1186/s13045-020-00857-7

The article indicates that HNF4A and its long non-coding RNA HNF4A-AS1 drive the progression of neuroblastoma by promoting aerobic glycolysis. HNF4A-AS1 binds to hnRNPU to activate CTCF and regulate glycolysis genes. Targeting this axis can inhibit tumors. High expression is associated with poor prognosis in patients.

2. Zhang, Yu, et al. "RNA-binding protein HnRNPU regulates proliferation and ferroptosis in colon adenocarcinoma by stabilizing the mRNA of system xc−." Experimental & Molecular Medicine (2025): 1-13. https://doi.org/10.1038/s12276-025-01569-z

The article indicates that HnRNPU is highly expressed in colon cancer and is associated with poor prognosis. It promotes glutathione synthesis by binding and stabilizing the mRNAs of SLC7A11 and SLC3A2, thereby inhibiting ferroptosis and promoting tumor proliferation. Targeting HnRNPU holds therapeutic potential.

3. Shi, Zhen-duo, et al. "Targeting HNRNPU to overcome cisplatin resistance in bladder cancer." Molecular cancer 21.1 (2022): 37. https://doi.org/10.1186/s12943-022-01517-9

The article indicates that HnRNPU is highly expressed in bladder cancer and is associated with drug resistance and poor prognosis. Through genome-wide CRISPR screening, it was confirmed that knocking out HnRNPU can inhibit tumors and regulate DNA repair genes, enhancing cisplatin sensitivity. Targeting HnRNPU is expected to overcome drug resistance.

4. Cai, Yujie, et al. "Microglial circ-UBE2K exacerbates depression by regulating parental gene UBE2K via targeting HNRNPU." Theranostics 14.10 (2024): 4058. https://doi.org/10.7150/thno.96890

The article indicates that circ-UBE2K is highly expressed in patients with depression and in model mice. It binds to HnRNPU to form a complex, upregulating its parent gene UBE2K, leading to abnormal activation of microglia and neuroinflammation, thereby promoting the occurrence of depression. Targeting this axis may be a potential therapeutic strategy.

5. Han, Bo-yue, et al. "HNRNPU promotes the progression of triple-negative breast cancer via RNA transcription and alternative splicing mechanisms." Cell Death & Disease 13.11 (2022): 940. https://doi.org/10.1038/s41419-022-05376-6

The article indicates that HnRNPU is highly expressed in triple-negative breast cancer and is a key oncogenic factor. It regulates RNA transcription and splicing by cooperating with DDX5, activates the Wnt and PI3K-Akt-mTOR pathways, thereby promoting tumor progression. HnRNPU has the potential to become a therapeutic target.

Creative Biolabs: HNRNPU Antibodies for Research

Creative Biolabs specializes in the production of high-quality HNRNPU antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom HNRNPU Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our HNRNPU antibodies, custom preparations, or technical support, contact us at email.